Meeting of the Board of Scientific Counselors, National Center for Injury Prevention and Control, 41442-41443 [2024-10301]
Download as PDF
<![CDATA[
41442
Federal Register / Vol. 89, No. 93 / Monday, May 13, 2024 / Notices
to complete the baseline survey and
three quarterly surveys, regardless of
how the respondent chooses to
complete it (i.e., self-administered
online or NASTAD staff-administered
by phone or videoconferencing). CDC
requests OMB approval for an estimated
233 annual burden hours. There is no
cost to survey participants other than
their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Respondent
All participating SSPs .....................................
All participating SSPs .....................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–10358 Filed 5–10–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting of the Board of Scientific
Counselors, National Center for Injury
Prevention and Control
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
Notice of open and closed
meeting.
ACTION:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the Board of
Scientific Counselors, National Center
for Injury Prevention and Control (BSC,
NCIPC). This meeting will take place in
person and virtually and is partially
open to the public.
SUMMARY:
The meeting will be held on June
5, 2024, from 1 p.m. to 4 p.m., EDT
(Closed); and June 6, 2024, from 10 a.m.
to 3:30 p.m., EDT (Open). The public
comment period will be at the end of
the open session of the meeting on June
6, 2024, from 3:10 p.m. to 3:25 p.m.,
EDT.
DATES:
Centers for Disease Control
and Prevention, Chamblee Campus,
Building 106, Conference Room 1–B,
4770 Buford Highway NE, Atlanta,
Georgia 30341. The conference room
will have seating for approximately 100
people for the open session of the
meeting.
lotter on DSK11XQN23PROD with NOTICES1
ADDRESSES:
VerDate Sep<11>2014
21:33 May 10, 2024
Number of
respondents
Form
Jkt 262001
Strengthening Syringe Services Programs
Baseline Survey.
Strengthening Syringe Services Programs
Quarterly Survey.
Please note that the meeting location
is a federal facility and in-person access
is limited to United States citizens
unless prior authorizations, taking up to
30 to 60 days, have been made. Visitors
must follow all directions for access to
CDC facilities. Directions for visitors to
CDC, including safety requirements
related to COVID–19, are available at
https://www.cdc.gov/screening/
visitors.html.
If you wish to attend the open session
of the meeting in person, please submit
a request by email to Mrs. Tonia Lindley
at TLindley@cdc.gov at least 5 business
days in advance of the meeting.
If you wish to attend the open session
of the meeting virtually, please register
in advance by accessing the link at:
https://cdc.zoomgov.com/webinar/
register/WN_X5RXABmES3u_
tsbMJdSJkg. Instructions to access the
Zoom virtual meeting will be provided
in the link following registration.
FOR FURTHER INFORMATION CONTACT:
Christopher R. Harper, Ph.D.,
Designated Federal Officer, Board of
Scientific Counselors, National Center
for Injury Prevention and Control,
Centers for Disease Control and
Prevention, 4770 Buford Highway NE,
Mailstop S–1069, Atlanta, Georgia
30341. Telephone: (404) 718–8330;
Email: ncipcbsc@cdc.gov.
SUPPLEMENTARY INFORMATION: Portions
of the meeting referenced above will be
closed to the public in accordance with
provisions set forth in section 552b(c)(4)
and (6), Title 5, U.S.C., and the
Determination of the Director, Office of
Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for
Disease Control and Prevention (CDC),
pursuant to 5 U.S.C. 1009(d) (Pub. L.
92–463, as amended).
Purpose: The Board of Scientific
Counselors, National Center for Injury
Prevention and Control (BSC, NCIPC)
will: (1) conduct, encourage, cooperate
with, and assist other appropriate public
health authorities, scientific
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden per
response
(hours)
200
1
25/60
200
3
15/60
institutions, and scientists in the
conduct of research, investigations,
experiments, demonstrations, and
studies relating to the causes and
strategies related to the prevention of
injury, overdose, and violence; (2) assist
States and other entities in preventing
intentional and unintentional injuries,
and to promote health and well-being;
and (3) make recommendations of grants
and cooperative agreements for research
and prevention activities related to
injury, overdose, and violence. The
BSC, NCIPC makes recommendations
regarding policies, strategies, objectives,
and priorities and reviews progress
toward injury, overdose, and violence
prevention. The Board also provides
advice on the appropriate balance of
intramural and extramural research and
provides guidance on the needs,
structure, progress, and performance of
intramural programs. Further, the Board
provides guidance on extramural
scientific program matters.
Additionally, the Board provides
second-level scientific and
programmatic review of applications for
research grants, cooperative agreements,
and training grants related to injury,
overdose, and violence prevention, and
recommends approval of projects that
merit further consideration for funding
support. The Board also provides
feedback and input on strategic plans,
resources, and priority publications
related to injury, overdose, and violence
prevention.
Matters to be Considered: The closed
session of the meeting (Day 1) will focus
on the secondary peer review of
extramural research grant applications
received in response to three (3) Notices
of Funding Opportunity: RFA–CE–22–
003—‘‘Rigorously Evaluating Programs
and Policies to Prevent Child Sexual
Abuse (CSA)’’; RFA–CE–24–012—
‘‘Rigorous Evaluation of Policy-Level
Interventions to Prevent Overdose
(R01)’’; and RFA–CE–24–030—
‘‘Research Grants for Preventing
E:\FR\FM\13MYN1.SGM
13MYN1
Federal Register / Vol. 89, No. 93 / Monday, May 13, 2024 / Notices
Violence and Violence Related Injury
(R01).’’ The open session of the meeting
(Day 2) will include discussions on
Enhancing CDC’s Efforts to Promote
Mental Health and Reduce Overdose
and Suicide: CDC’s New Behavioral
Health Coordinating Unit; the 2024
National Strategy for Suicide Prevention
and Action Plan; Updated Sexual
Violence Research Priorities; Leveraging
High-Quality Data from the Violence
Against Children and Youth Survey to
Demonstrate Reductions in Population
Prevalence of Violence against Children;
and Division of Overdose Prevention
Portfolio Review, 2018–2023: Informing
the 2025 Update to the Overdose
Prevention Research Priorities. Agenda
items are subject to change as priorities
dictate.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–10301 Filed 5–10–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2022–E–1984; FDA–
2022–E–1986]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; JEMPERLI
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for JEMPERLI and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of applications to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that human
biological product.
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
21:33 May 10, 2024
Jkt 262001
Anyone with knowledge that any
of the dates as published (see
SUPPLEMENTARY INFORMATION) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by July 12, 2024.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
November 12, 2024. See ‘‘Petitions’’ in
the SUPPLEMENTARY INFORMATION section
for more information.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. The https://
www.regulations.gov electronic filing
system will accept comments until
11:59 p.m. Eastern Time at the end of
July 12, 2024. Comments received by
mail/hand delivery/courier (for written/
paper submissions) will be considered
timely if they are received on or before
that date.
DATES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
41443
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket Nos. FDA–
2022–E–1984 and FDA–2022–E–1986
for ‘‘Determination of Regulatory
Review Period for Purposes of Patent
Extension; JEMPERLI.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with § 10.20 (21
CFR 10.20) and other applicable
disclosure law. For more information
about FDA’s posting of comments to
public dockets, see 80 FR 56469,
September 18, 2015, or access the
information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
E:\FR\FM\13MYN1.SGM
13MYN1
]]>Agencies
[Federal Register Volume 89, Number 93 (Monday, May 13, 2024)]
[Notices]
[Pages 41442-41443]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10301]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Meeting of the Board of Scientific Counselors, National Center
for Injury Prevention and Control
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of open and closed meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting for the Board of Scientific Counselors, National
Center for Injury Prevention and Control (BSC, NCIPC). This meeting
will take place in person and virtually and is partially open to the
public.
DATES: The meeting will be held on June 5, 2024, from 1 p.m. to 4 p.m.,
EDT (Closed); and June 6, 2024, from 10 a.m. to 3:30 p.m., EDT (Open).
The public comment period will be at the end of the open session of the
meeting on June 6, 2024, from 3:10 p.m. to 3:25 p.m., EDT.
ADDRESSES: Centers for Disease Control and Prevention, Chamblee Campus,
Building 106, Conference Room 1-B, 4770 Buford Highway NE, Atlanta,
Georgia 30341. The conference room will have seating for approximately
100 people for the open session of the meeting.
Please note that the meeting location is a federal facility and in-
person access is limited to United States citizens unless prior
authorizations, taking up to 30 to 60 days, have been made. Visitors
must follow all directions for access to CDC facilities. Directions for
visitors to CDC, including safety requirements related to COVID-19, are
available at https://www.cdc.gov/screening/visitors.html.
If you wish to attend the open session of the meeting in person,
please submit a request by email to Mrs. Tonia Lindley at
[email protected] at least 5 business days in advance of the meeting.
If you wish to attend the open session of the meeting virtually,
please register in advance by accessing the link at: https://cdc.zoomgov.com/webinar/register/WN_X5RXABmES3u_tsbMJdSJkg.
Instructions to access the Zoom virtual meeting will be provided in the
link following registration.
FOR FURTHER INFORMATION CONTACT: Christopher R. Harper, Ph.D.,
Designated Federal Officer, Board of Scientific Counselors, National
Center for Injury Prevention and Control, Centers for Disease Control
and Prevention, 4770 Buford Highway NE, Mailstop S-1069, Atlanta,
Georgia 30341. Telephone: (404) 718-8330; Email: [email protected].
SUPPLEMENTARY INFORMATION: Portions of the meeting referenced above
will be closed to the public in accordance with provisions set forth in
section 552b(c)(4) and (6), Title 5, U.S.C., and the Determination of
the Director, Office of Strategic Business Initiatives, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention
(CDC), pursuant to 5 U.S.C. 1009(d) (Pub. L. 92-463, as amended).
Purpose: The Board of Scientific Counselors, National Center for
Injury Prevention and Control (BSC, NCIPC) will: (1) conduct,
encourage, cooperate with, and assist other appropriate public health
authorities, scientific institutions, and scientists in the conduct of
research, investigations, experiments, demonstrations, and studies
relating to the causes and strategies related to the prevention of
injury, overdose, and violence; (2) assist States and other entities in
preventing intentional and unintentional injuries, and to promote
health and well-being; and (3) make recommendations of grants and
cooperative agreements for research and prevention activities related
to injury, overdose, and violence. The BSC, NCIPC makes recommendations
regarding policies, strategies, objectives, and priorities and reviews
progress toward injury, overdose, and violence prevention. The Board
also provides advice on the appropriate balance of intramural and
extramural research and provides guidance on the needs, structure,
progress, and performance of intramural programs. Further, the Board
provides guidance on extramural scientific program matters.
Additionally, the Board provides second-level scientific and
programmatic review of applications for research grants, cooperative
agreements, and training grants related to injury, overdose, and
violence prevention, and recommends approval of projects that merit
further consideration for funding support. The Board also provides
feedback and input on strategic plans, resources, and priority
publications related to injury, overdose, and violence prevention.
Matters to be Considered: The closed session of the meeting (Day 1)
will focus on the secondary peer review of extramural research grant
applications received in response to three (3) Notices of Funding
Opportunity: RFA-CE-22-003--``Rigorously Evaluating Programs and
Policies to Prevent Child Sexual Abuse (CSA)''; RFA-CE-24-012--
``Rigorous Evaluation of Policy-Level Interventions to Prevent Overdose
(R01)''; and RFA-CE-24-030--``Research Grants for Preventing
[[Page 41443]]
Violence and Violence Related Injury (R01).'' The open session of the
meeting (Day 2) will include discussions on Enhancing CDC's Efforts to
Promote Mental Health and Reduce Overdose and Suicide: CDC's New
Behavioral Health Coordinating Unit; the 2024 National Strategy for
Suicide Prevention and Action Plan; Updated Sexual Violence Research
Priorities; Leveraging High-Quality Data from the Violence Against
Children and Youth Survey to Demonstrate Reductions in Population
Prevalence of Violence against Children; and Division of Overdose
Prevention Portfolio Review, 2018-2023: Informing the 2025 Update to
the Overdose Prevention Research Priorities. Agenda items are subject
to change as priorities dictate.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-10301 Filed 5-10-24; 8:45 am]
BILLING CODE 4163-18-P
